{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-065308","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.535182+00:00","generated_at":"2026-05-16T00:48:13.923986+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"low","headline":"Palvella announces Phase 3 SELVA topline results for QTORIN in lymphatic malformations; specifics not in filing excerpt","bullets":["Topline data from Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations announced on Feb 24, 2026.","Investor conference call held at 8:00 a.m. ET; presentation slides furnished as Exhibit 99.1.","Exact efficacy and safety endpoints not disclosed in this filing excerpt; full results expected in the presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-065308","json":"https://secwatch.observer/filing/0001193125-26-065308.json","markdown":"https://secwatch.observer/filing/0001193125-26-065308.md","text":"https://secwatch.observer/filing/0001193125-26-065308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/0001193125-26-065308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:48:13.923986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}